BMS MDD CORE 07
A Multicenter, Randomized, Double-blind, Active-Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression
| Protocol | |
|---|
| Identifier | CN162007 |
|---|
| UID | bbda634f-9c76-4a33-917f-8e0221ff9710 |
|---|
| Status | Done - Archived |
|---|
| Phase | 2b |
|---|
| Category | Major Depressive Disorder / Adult |
|---|
| Launch Year | 2011 |
|---|
| NCT Number | - |
|---|
| Created | 2011-04-06 16:37 |
|---|
| Last Updated | 2011-04-06 16:37 |
|---|
Description
Key Elements:
• The purpose of this trial is to establish the efficacy of study drug BMS-820836 compared to fixed doses of Duloxetine (Cymbalata) and Escitalopram (Lexapro).
• All subjects will be receiving an active drug, but all treatment arms will receiving at least one placebo as well.
• Study administration will be 4 tablets daily.
• Subjects who are taking exclusionary meds can be washed out, as there is a 28 day screening window.
• The study is up to 20 weeks long in duration, consisting of 17 office visits.
• $45 per visit.
Comment
No comment.
